DDInter672 DDInter927
Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. It is used to restore serotonergic function in the treatment of depression and anxiety.[L8513,L8516,L8522] Escitalopram is approximately 150 times more potent than citalopram’s R-enantiomer and is responsible for the vast majority of citalopram’s clinical activity, with some evidence suggesting that the R-enantiomer of racemic citalopram actively dampens the activity of escitalopram rather than existing simply as an inactive enantiomer.[A39738,A185819] Amongst SSRIs, escitalopram exerts the highest degree of selectivity for the serotonin transporter (SERT) relative to other off-targets which may explain its lower rates of adverse effects as compared to other agents in this class. Escitalopram also differentiates itself from
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Escitalopram {u} (Compound) resembles {v} (Compound) Citalopram
Escitalopram {u} (Compound) binds {v} (Gene) CYP3A4
Escitalopram {u} (Compound) upregulates {v} (Gene) RRS1
Escitalopram {u} (Compound) palliates {v} (Disease) bipolar disorder
Escitalopram {u} (Compound) is included by {v} (Pharmacologic Class) Serotonin Uptake Inhibitors
Escitalopram {u} (Compound) downregulates {v} (Gene) VAT1
Escitalopram {u} (Compound) causes {v} (Side Effect) Dysmenorrhoea
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Miconazole
Escitalopram {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ivacaftor
Escitalopram {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Thiethylperazine
Escitalopram (Compound) resembles Citalopram (Compound)
Escitalopram (Compound) binds CYP3A4 (Gene)
Escitalopram (Compound) upregulates RRS1 (Gene)
Escitalopram (Compound) palliates bipolar disorder (Disease)
Escitalopram (Compound) is included by Serotonin Uptake Inhibitors (Pharmacologic Class)
Escitalopram (Compound) downregulates VAT1 (Gene)
Escitalopram (Compound) causes Dysmenorrhoea (Side Effect)
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Miconazole
Escitalopram may cause a minor interaction that can limit clinical effects when taken with Ivacaftor
Escitalopram may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine